Emergent BioSolutions Inc. (NYSE:EBS) Shares Purchased by Values First Advisors Inc.

Values First Advisors Inc. raised its position in Emergent BioSolutions Inc. (NYSE:EBS) by 101.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 307,892 shares of the biopharmaceutical company’s stock after purchasing an additional 155,193 shares during the quarter. Values First Advisors Inc.’s holdings in Emergent BioSolutions were worth $739,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of Emergent BioSolutions by 3.4% in the 1st quarter. BlackRock Inc. now owns 9,258,383 shares of the biopharmaceutical company’s stock valued at $95,917,000 after buying an additional 303,165 shares during the period. State Street Corp increased its position in shares of Emergent BioSolutions by 25.7% in the 2nd quarter. State Street Corp now owns 6,794,144 shares of the biopharmaceutical company’s stock valued at $49,937,000 after purchasing an additional 1,388,594 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Emergent BioSolutions by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 5,191,486 shares of the biopharmaceutical company’s stock valued at $108,969,000 after purchasing an additional 101,059 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Emergent BioSolutions by 44.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,561,050 shares of the biopharmaceutical company’s stock worth $5,308,000 after purchasing an additional 482,632 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Emergent BioSolutions by 33.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,368,661 shares of the biopharmaceutical company’s stock worth $56,199,000 after purchasing an additional 342,964 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Stock Down 2.3 %

NYSE EBS traded down $0.06 on Friday, reaching $2.53. The stock had a trading volume of 1,089,156 shares, compared to its average volume of 2,092,167. Emergent BioSolutions Inc. has a 12-month low of $1.42 and a 12-month high of $13.67. The business’s 50-day moving average price is $2.27 and its 200 day moving average price is $2.44. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.04 and a quick ratio of 0.54.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.44). Emergent BioSolutions had a negative net margin of 72.11% and a negative return on equity of 37.35%. The company had revenue of $276.60 million during the quarter, compared to analyst estimates of $247.63 million. During the same period in the previous year, the firm posted ($0.31) EPS. Equities research analysts forecast that Emergent BioSolutions Inc. will post -13.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. StockNews.com raised Emergent BioSolutions from a “sell” rating to a “hold” rating in a research report on Tuesday, December 12th. Benchmark upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Thursday, March 7th.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care.